Money
Eli Lilly and Insilico Forge $2.75 Billion Partnership for AI-Developed Pharmaceuticals
Eli Lilly has entered a $2.75 billion agreement with Insilico, involving an upfront payment of $115 million to advance AI-discovered drugs to market.
Editorial Staff
1 min read
Eli Lilly has announced a significant partnership with Insilico, committing $2.75 billion to bring AI-developed pharmaceuticals to the global market.
The agreement includes an upfront payment of $115 million, which will facilitate the initial stages of drug development and commercialization.
This collaboration highlights the increasing integration of artificial intelligence in pharmaceutical research and development, potentially enhancing throughput and efficiency in drug discovery.